An observational study in Neoplasms, Second Primary, sponsored by Kantonsspital Graubuenden. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-12-13.
Sponsored by Kantonsspital Graubuenden · Observational
Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having had radiation therapy for rectal cancer. Twenty-five patients are included in this study. Planning CT scans are used for comparison of dose distribution and calculation of second cancer risk.
A model-based Analysis calculating the organ-specific excess lifetime attributable risk using the planning CT data sets of 25 patients to estimate second cancer risk for patients after radiotherapy for rectal cancer comparing conventional 3DCRT with VAMT techniques.
247 studies on the registry are indexed under Neoplasms, Second Primary; 48 are open to participants now.
This study's enrollment of 25 is below the median of 290 across 60 observational studies indexed under Neoplasms, Second Primary.
Browse Neoplasms, Second Primary studies →Kantonsspital Graubuenden is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients having had radiation therapy for rectal cancer. Estimation of second cancer risk using data from planning CTs comparing dose Distribution using different Radiation therapy techniques (3DCRT vs VMAT).
Exclusion Criteria:
No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)
LAR is calculated for variable Ages at exposure
Time frame: 60 years (model-based calculation)
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kantonsspital Graubuenden